Dabrafenib
Common brands: Tafinlar, Mekinist, Opdivo, Yervoy, Keytruda
Top reporter: Novartis Pharmaceuticals Corporation
Corticosteroid [EPC]Programmed Death Receptor-1 Blocking Antibody [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Kinase Inhibitor [EPC]CTLA-4-directed Blocking Antibody [EPC]
20,691
Total Reports
10,115
Serious Reports
4,365
Death Reports
30
Reported Reactions
Death Report Ratio: High (21.10%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Dabrafenib.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | PYREXIA | 4,045 | |
| 2 | DEATH | 2,862 | |
| 3 | MALIGNANT NEOPLASM PROGRESSION | 1,737 | |
| 4 | FATIGUE | 1,407 | |
| 5 | NAUSEA | 1,382 | |
| 6 | CHILLS | 1,314 | |
| 7 | RASH | 1,156 | |
| 8 | VOMITING | 971 | |
| 9 | DIARRHOEA | 957 | |
| 10 | HEADACHE | 737 | |
| 11 | ASTHENIA | 709 | |
| 12 | MALAISE | 620 | |
| 13 | DECREASED APPETITE | 579 | |
| 14 | ARTHRALGIA | 569 | |
| 15 | PRODUCT USE IN UNAPPROVED INDICATION | 532 | |
| 16 | VISUAL IMPAIRMENT | 520 | |
| 17 | PAIN | 492 | |
| 18 | METASTASES TO CENTRAL NERVOUS SYSTEM | 490 | |
| 19 | DRUG INEFFECTIVE | 479 | |
| 20 | METASTATIC MALIGNANT MELANOMA | 471 | |
| 21 | MALIGNANT MELANOMA | 435 | |
| 22 | DISEASE PROGRESSION | 415 | |
| 23 | DYSPNOEA | 408 | |
| 24 | DIZZINESS | 378 | |
| 25 | COUGH | 356 | |
| 26 | PNEUMONIA | 347 | |
| 27 | DEHYDRATION | 346 | |
| 28 | OFF LABEL USE | 345 | |
| 29 | GENERAL PHYSICAL HEALTH DETERIORATION | 332 | |
| 30 | VISION BLURRED | 332 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.